BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24007441)

  • 1. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig.
    Pinelli DF; Wagener ME; Liu D; Yamniuk A; Tamura J; Grant S; Larsen CP; Suri A; Nadler SG; Ford ML
    Am J Transplant; 2013 Nov; 13(11):3021-30. PubMed ID: 24007441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
    Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
    J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade.
    Ferrer IR; Wagener ME; Song M; Kirk AD; Larsen CP; Ford ML
    Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20701-6. PubMed ID: 22143783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
    Liu H; Qiu F; Wang Y; Zeng Q; Liu C; Chen Y; Liang CL; Zhang Q; Han L; Dai Z
    Front Immunol; 2019; 10():306. PubMed ID: 30863408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD154 blockade alters innate immune cell recruitment and programs alloreactive CD8+ T cells into KLRG-1(high) short-lived effector T cells.
    Ferrer IR; Wagener ME; Song M; Ford ML
    PLoS One; 2012; 7(7):e40559. PubMed ID: 22792369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.
    Kim SC; Wakwe W; Higginbotham LB; Mathews DV; Breeden CP; Stephenson AC; Jenkins J; Strobert E; Price K; Price L; Kuhn R; Wang H; Yamniuk A; Suchard S; Farris AB; Pearson TC; Larsen CP; Ford ML; Suri A; Nadler S; Adams AB
    Am J Transplant; 2017 May; 17(5):1182-1192. PubMed ID: 28097811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependency of direct pathway CD4+ T cells on CD40-CD154 costimulation is determined by nature and microenvironment of primary contact with alloantigen.
    van Maurik A; Fazekas de St Groth B; Wood KJ; Jones ND
    J Immunol; 2004 Feb; 172(4):2163-70. PubMed ID: 14764682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice.
    Lee JH; Ha J; Kim SH; Kim SJ
    J Korean Med Sci; 2006 Dec; 21(6):1005-11. PubMed ID: 17179677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
    Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
    Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.
    Sho M; Sandner SE; Najafian N; Salama AD; Dong V; Yamada A; Kishimoto K; Harada H; Schmitt I; Sayegh MH
    Ann Surg; 2002 Nov; 236(5):667-75. PubMed ID: 12409674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Costimulation Blockade-Induced Regulatory T Cells Demonstrate Dominant and Specific Tolerance to Porcine Islet Xenografts.
    Wu J; Hu M; Qian YW; Hawthorne WJ; Burns H; Liuwantara D; Alexander SI; Yi S; O'Connell PJ
    Transplantation; 2017 Jul; 101(7):1587-1599. PubMed ID: 27653300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts.
    Jones TR; Ha J; Williams MA; Adams AB; Durham MM; Rees PA; Cowan SR; Pearson TC; Larsen CP
    J Immunol; 2002 Feb; 168(3):1123-30. PubMed ID: 11801646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection.
    Ardjomand N; McAlister JC; Rogers NJ; Tan PH; George AJ; Larkin DF
    Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3899-905. PubMed ID: 12939307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients.
    Zhai Y; Meng L; Gao F; Busuttil RW; Kupiec-Weglinski JW
    J Immunol; 2002 Oct; 169(8):4667-73. PubMed ID: 12370407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.
    Markees TG; Phillips NE; Gordon EJ; Noelle RJ; Shultz LD; Mordes JP; Greiner DL; Rossini AA
    J Clin Invest; 1998 Jun; 101(11):2446-55. PubMed ID: 9616216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion.
    Cordoba F; Wieczorek G; Audet M; Roth L; Schneider MA; Kunkler A; Stuber N; Erard M; Ceci M; Baumgartner R; Apolloni R; Cattini A; Robert G; Ristig D; Munz J; Haeberli L; Grau R; Sickert D; Heusser C; Espie P; Bruns C; Patel D; Rush JS
    Am J Transplant; 2015 Nov; 15(11):2825-36. PubMed ID: 26139432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation.
    Gilson CR; Milas Z; Gangappa S; Hollenbaugh D; Pearson TC; Ford ML; Larsen CP
    J Immunol; 2009 Aug; 183(3):1625-35. PubMed ID: 19592649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization.
    Xu H; Yan J; Huang Y; Chilton PM; Ding C; Schanie CL; Wang L; Ildstad ST
    Blood; 2008 Mar; 111(6):3266-75. PubMed ID: 17827394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.